IN8BIO grants 60,000 stock options to president

IN8BIO, INC. reported that President and COO Kate Rochlin received a grant of employee stock options covering 60,000 shares of common stock.

Rhea-AI Filing Summary

IN8BIO, INC. reported that President and COO Kate Rochlin received a grant of employee stock options covering 60,000 shares of common stock. The options have an exercise price of $1.58 per share and expire on May 9, 2036.

These compensation-related options were awarded with no cash paid by the executive at grant. According to the vesting schedule, 25% of the option shares vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, as long as she continues providing service through each date. After this grant, she holds options for 60,000 underlying shares directly.

Insider Trade Summary

Grant/Award: 60,000 shares

Grant/Award 1 txn

Insider Rochlin Kate

Role President and COO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	60,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 60,000 contracts (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.

Key Figures

Option grant size: 60,000 options Exercise price: $1.58 per share Expiration date: May 9, 2036 +3 more

6 metrics

Option grant size 60,000 options Employee stock option award to President and COO

Exercise price $1.58 per share Strike price of employee stock options

Expiration date May 9, 2036 Option term end date

Post-grant option holdings 60,000 options Total derivative shares following transaction

Initial vesting date November 9, 2026 First 25% of options vest

Final vesting date May 9, 2028 Last 25% of options vest

Key Terms

Employee Stock Option (right to buy), exercise price, vest, expiration date, +1 more

5 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.5800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"shares subject to the option shall vest on each of November 9, 2026"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

expiration date financial

"expiration_date: 2036-05-09T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

derivative securities financial

"transaction_type: derivative"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IN8BIO (INAB) disclose about President and COO Kate Rochlin?

IN8BIO disclosed that President and COO Kate Rochlin received a grant of stock options for 60,000 shares. These options are part of her equity compensation and give her the right to buy common stock at a fixed price if vesting conditions are met.

How many IN8BIO (INAB) shares are covered by Kate Rochlin’s new options?

The new option grant covers 60,000 shares of IN8BIO common stock. This means she can potentially purchase up to 60,000 shares at the preset exercise price if all vesting milestones are satisfied over time.

What is the exercise price and expiration date of Kate Rochlin’s IN8BIO options?

The options have an exercise price of $1.58 per share and expire on May 9, 2036. This fixed price lets her buy shares at $1.58 if she exercises before expiration and after the options vest.

How do Kate Rochlin’s IN8BIO (INAB) stock options vest over time?

The options vest in four equal installments of 25% each on November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028. Vesting requires that she continue providing service through each scheduled vesting date.

Did Kate Rochlin buy or sell any IN8BIO (INAB) shares in this Form 4?

This Form 4 reports a grant of employee stock options, not a market purchase or sale of shares. It reflects a compensation-related acquisition of derivative securities rather than open-market trading in IN8BIO common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rochlin Kate

(Last) (First) (Middle)

C/O IN8BIO, INC.

350 5TH AVE. SUITE 5330

(Street)

NEW YORK NEW YORK 10118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.58	05/09/2026		A		60,000		(1)	05/09/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.

	/s/ William Ho, Attoney-in-Fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)